Altered serine/threonine kinase activity in schizophrenia

Brain Research

Volumn 1568, Issue , 2014, Pages 42-54

  McGuire, Jennifer L ^d   Hammond, John H ^a   Yates, Stefani D ^a   Chen, Dongquan ^b   Haroutunian, Vahram ^c   Meador Woodruff, James H ^a   McCullumsmith, Robert E ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Immune trafficking; Ion homeostasis; Kinome; Phosphopeptides; Postmortem; Synaptic remodeling

Indexed keywords

ADENOSINE TRIPHOSPHATE; ION; PEPTIDE; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL MOTION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NONHUMAN; NUCLEIC ACID METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; RAT; SCHIZOPHRENIA; VERY ELDERLY; ANIMAL; BRAIN CORTEX; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

AGED; AGED, 80 AND OVER; ANIMALS; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 84902548237     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.04.029     Document Type: Article

References (101)

1. D.D. Adams, J.G. Knight, and A. Ebringer The autoimmune model of schizophrenia ISRN Psychiatry 2012 2012 758072
2. K.A. Albert et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia Arch. Gen. Psychiatry 59 2002 705 712
3. M. Amadio, F. Battaini, and A. Pascale The different facets of protein kinases C: old and new players in neuronal signal transduction pathways Pharmacol. Res. 54 2006 317 325
4. S. Amar et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia Int. J. Neuropsychopharmacol. 11 2008 197 205
5. J.A. Appuhamy et al. Effects of AMP-activated protein kinase (AMPK) signaling and essential amino acids on mammalian target of rapamycin (mTOR) signaling and protein synthesis rates in mammary cells J. Dairy Sci. 97 2014 419 429
6. R. Arsenault, P. Griebel, and S. Napper Peptide arrays for kinome analysis: new opportunities and remaining challenges Proteomics 11 2011 4595 4609
7. T.A. Bayer et al. Evidence for activation of microglia in patients with psychiatric illnesses Neurosci. Lett. 271 1999 126 128
8. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu. Rev. Pharmacol. Toxicol. 49 2009 327 347
9. J.M. Beaulieu A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health J. Psychiatry Neurosci. 37 2012 7 16
10. W. Beumer et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes J. Leukocyte Biol. 92 2012 959 975
11. R. Bridges et al. Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (system xc-) to normal and pathological glutamatergic signaling Pharmacol. Rev. 64 2012 780 802
12. S.L. Bronson et al. Individual differences in maternal response to immune challenge predict offspring behavior: contribution of environmental factors Behav. Brain Res. 220 2011 55 64
13. S.E. Canetta, and A.S. Brown Prenatal infection, maternal immune activation, and risk for schizophrenia Transl. Neurosci 3 2012 320 327
14. M. Capra et al. Frequent alterations in the expression of serine/threonine kinases in human cancers Cancer Res. 66 2006 8147 8154
15. N.C. Carty /sb:authors> et al. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications Transl. Psychiatry 2 2012 e137
16. M.A. Castillo et al. Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex Biol. Psychiatry 67 2010 208 216
17. L. Choe et al. 8-Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease Proteomics 7 2007 3651 3660
18. C. Cohen-Saidon et al. Dynamics and variability of ERK2 response to EGF in individual living cells Mol. Cell. 36 2009 885 893
19. A. Cornet et al. Role of astrocytes in antigen presentation and naive T-cell activation J. Neuroimmunol. 106 2000 69 77
20. J. Coyle The glutamatergic dysfunction hypothesis for schizophrenia Harvard Rev. Psychiatry 3 1996 241 253
21. J. Coyle, G. Tsai, and D. Goff Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia Ann. N.Y. Acad. Sci. 1003 2003 318 327
22. R.M. Craddock et al. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms PLoS One 2 2007 e692
23. C.A. DeBoy et al. FLT-3 expression and function on microglia in multiple sclerosis Exp. Mol. Pathol. 89 2010 109 116
24. H. Dehghani, C. Reith, and A.C. Hahnel Subcellular localization of protein kinase C delta and epsilon affects transcriptional and post-transcriptional processes in four-cell mouse embryos Reproduction 130 2005 453 465
25. T. Del'guidice, and J.M. Beaulieu Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo Mol. Pharmacol. 73 2008 1339 1342
26. R.C. Drexhage et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces Int. J. Neuropsychopharmacol. 14 2011 746 755
27. E.S. Emamian, M. Karayiorgou, and J.A. Gogos Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia J. Neurosci. 24 2004 1561 1564
28. J.A. Engelman et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc. Nat. Acad. Sci. U.S.A. 102 2005 3788 3793
29. J.A. English et al. The neuroproteomics of schizophrenia Biol. Psychiatry 69 2011 163 172
30. A.M. Fineberg, and L.M. Ellman Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia Biol. Psychiatry 73 2013 951 966
31. A.J. Funk et al. Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia Neuropsychopharmacology 37 2012 896 905
32. L. Garey When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits J. Anat. 217 2010 324 333
33. M.E. Gibbs et al. ATP derived from astrocytes modulates memory in the chick Neuron Glia Biol. 7 2011 177 186
34. J. Gien et al. Peroxisome proliferator activated receptor gamma-rho-kinase interactions contribute to vascular remodeling after intrauterine pulmonary hypertension Am. J. Physiol. Lung Cell. Mol. Physiol 2013
35. W. Gobel, and F. Helmchen In vivo calcium imaging of neural network function Physiology 22 2007 358 365
36. L. Goentoro, and M.W. Kirschner Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling Mol. Cell. 36 2009 872 884
37. L. Goentoro et al. The incoherent feedforward loop can provide fold-change detection in gene regulation Mol. Cell. 36 2009 894 899
38. V. Goubard, E. Fino, and L. Vanance Contribution of astrocytic glutamate and GABA uptake to corticostriatal information processing J. Physiol. 589 2011 2301 2319
39. P. Greengard, P.B. Allen, and A.C. Nairn Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade Neuron 23 1999 435 447
40. P. Greengard The neurobiology of slow synaptic transmission Science 294 2001 1024 1030
41. C.G. Hahn et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia Nat. Med 12 2006 824 828
42. M. Halassa, T. Fellin, and P. Haydon The tripartite synapse: roles for gliotransmission in health and disease Trends Mol. Med. 13 2007 54 63
43. H. Hassanpoor, A. Fallah, and M. Raza New role for astroglia in learning: formation of muscle memory Med. Hypotheses 79 2012 770 773
44. A. Haupt et al. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics BMC Cancer 12 2012 38
45. G.D. Hoftman et al. Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance Schizophr. Bull. 2013
46. J. Hunsberger et al. The neurotrophic and neuroprotective effects of psychotropic agents Dialogues Clin. Neurosci 11 2009 333 348
47. J.S. Jarboe et al. Kinomic profiling approach identifies Trk as a novel radiation modulator Radiother. Oncol. 103 2012 380 387
48. L.B. Jones, N. Johnson, and W. Byne Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex Psychiatry Res. 114 2002 137 148
49. N. Kozlovsky, R.H. Belmaker, and G. Agam Low GSK-3 activity in frontal cortex of schizophrenic patients Schizophr. Res. 52 2001 101 105
50. M. Kreft et al. Regulated exocytosis and vesicle trafficking in astrocytes Ann. N.Y. Acad. Sci 1152 2009 30 42
51. Y. Kunii et al. Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1139 1143
52. Y. Kunii et al. Detailed DARPP-32 expression profiles in postmortem brains from patients with schizophrenia: an immunohistochemical study Med. Mol. Morphol. 44 2011 190 199
53. U.E. Lang et al. Molecular mechanisms of schizophrenia Cell Physiol. Biochem. 20 2007 687 702
54. M. Laruelle et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proc. Nat. Acad. Sci. U.S.A. 93 1996 9235 9240
55. M. Laruelle et al. Increased dopamine transmission in schizophrenia: relationship to illness phases Biol. Psychiatry 46 1999 56 72
56. D.A. Lewis et al. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia Biol. Psychiatry 46 1999 616 626
57. D.A. Lewis et al. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons Ann. N.Y. Acad. Sci 1003 2003 102 112
58. D.A. Lewis Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia Dialogues Clin. Neurosci. 11 2009 269 280
59. J. Li et al. Post-mortem interval effects on the phosphorylation of signaling proteins Neuropsychopharmacology 28 2003 1017 1025
60. X. Li et al. Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain J. Neurochem. 92 2005 701 704
61. S. Marenco, and D.R. Weinberger The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave Dev. Psychopathol. 12 2000 501 527
62. D. Martins-de-Souza et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia Eur. Arch. Psychiatry Clin. Neurosci. 259 2009 151 163
63. M. Mattson Glutamate and neurotrophic factors in neuronal plasticity and disease Ann. N.Y. Acad. Sci 2008 97 112
64. R.E. McCullumsmith, S.M. Clinton, and J.H. Meador-Woodruff Schizophrenia as a disorder of neuroplasticity Int. Rev. Neurobiol. 59 2004 19 45
65. R.E. McCullumsmith et al. Postmortem brain: an underutilized substrate for studying severe mental illness Neuropsychopharmacology 39 2014 65 87
66. S. Meeuwsen et al. Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli Glia 43 2003 243 253
67. H.Y. Meltzer, and S.M. Stahl The dopamine hypothesis of schizophrenia: a review Schizophr. Bull. 2 1976 19 76
68. B. Moghaddam Bringing order to the glutamate chaos in schizophrenia Neuron 40 2003 881 884
69. R. Molteni et al. Antipsychotic drug actions on gene modulation and signaling mechanisms Pharmacol. Ther. 124 2009 74 85
70. T. Oka et al. Dynamic changes of the phosphoproteome in postmortem mouse brains PLoS One 6 2011 e21405
71. R.C. Paolicelli et al. Synaptic pruning by microglia is necessary for normal brain development Science 333 2011 1456 1458
72. R.C. Paolicelli, and C.T. Gross Microglia in development: linking brain wiring to brain environment Neuron Glia Biol. 7 2011 77 83
73. V. Parpura et al. Glutamate - mediated astrocyte-neuron signaling Nature 369 1994 744 747
74. V. Parpura et al. Glial cells in (patho)physiology J. Neurochem. 121 2012 4 27
75. I. Patrushev et al. Subcellular location of astrocytic calcium stores favors extrasynaptic neuron-astrocyte communication Cell Calcium 54 2013 343 349
76. G. Perea, and A. Araque GLIA modulates synaptic transmission Brain Res. Rev. 63 2010 93 102
77. A. Pereira et al. Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs Int. J. Neuropsychopharmacol. 15 2012 1149 1160
78. J. Rapoport et al. The neurodevelopmental model of schizophrenia: update 2005 Mol. Psychiatry 10 2005 434 449
79. M. Rodriguez et al. The role of non-synaptic extracellular glutamate Brain Res. Bull. 93 2013 17 26
80. M.D. Rubio, V. Haroutunian, and J.H. Meador-Woodruff Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia Biol. Psychiatry 71 2012 906 914
81. A. Sakakibara et al. Microtubule dynamics in neuronal morphogenesis Open Biol 2013 3
82. M. Santello, C. Cali, and P. Bezzi Gliotransmission and the tripartite synapse Adv. Exp. Med. Biol. 970 2012 307 331
83. D. Schafer et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent maner Neuron 74 2012 691 705
84. D.P. Schafer, E.K. Lehrman, and B. Stevens The "quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS Glia 61 2013 24 36
85. T. Schwarz Mitochondrial trafficking in neurons Cold Spring Harb Perspect. Biol 5 2013
86. D. Shan et al. Update on the neurobiology of schizophrenia: a role for extracellular microdomains Minerva Psichiatr. 53 2012 233 249
87. D. Shan et al. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia Schizophr. Res. 144 2013 1 8
88. A.H. Sikkema et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery Cancer Res. 69 2009 5987 5995
89. R. Smith Moving molecules: mRNA trafficking in mammalian ologodendrocytes and neurons Neuroscientist 10 2004 495 500
90. A.H. Stephan, B.A. Barres, and B. Stevens The complement system: an unexpected role in synaptic pruning during development and disease Annu. Rev. Neurosci. 35 2012 369 389
91. J.E. Swatton et al. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain Eur. J. Neurosci. 19 2004 2711 2719
92. M. Tanaka et al. Astrocytic Ca2+ signals are required for the functional integrity of tripartite synapses Mol. Brain 6 2013 1 13
93. L.E. Trudeau Glutamate co-transmission as an emerging concept in monoamine neuron function J. Psychiatry Neurosci. 29 2004 296 310
94. G. Tsai et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains Arch. Gen. Psychiatry 52 1995 829 836
95. H. van Hattum et al. Development of a microarray detection method for galectin cancer proteins based on ligand binding Anal. Biochem. 434 2013 99 104
96. D. Verbich et al. Glial glutamate transport modulates dendritic spine head protrusions in the hippocampus Glia 60 2012 1067 1077
97. C.V. Vorhees et al. Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC Synapse 66 2012 725 737
98. C.K. Watts et al. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation Mol. Endocrinol. 9 1995 1804 1813
99. T. Yamauchi Neuronal Ca2+/calmodulin-dependent protein kinase II - discovery, progress in a quarter of a century, and perspective: implication for learning and memory Biol. Pharm. Bull. 28 2005 1342 1354
100. X. Yang et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data J. Biomed. Inform. 43 2010 376 384
101. Z.Q. Yuan et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2000 2324 2330